Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a fourth-quarter 2023 EPS loss of $(0.19), missing the consensus of $(0.16) and a bit higher than $(0.18) a year ago.
The company reported sales of $45.1 million, beating the consensus of $44.33 million.
Aurinia said it will immediately discontinue its future development of AUR200 and AUR300 research and development programs and prioritize resource allocation.
In January, Aurinia submitted its FDA Investigational New Drug application for AUR200, a potential therapy for B-cell mediated autoimmune diseases. Aurinia planned to initiate a Phase 1 study in the first half of …
Leave a Reply